Company Kuros Biosciences AG Swiss Exchange

Equities

CH0011025217

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sales per Business

Sales per region

Sector Bio Therapeutic Drugs

Inactive Instrument

End-of-day quote Swiss Exchange Other stock markets
- ^CHF	-

Apr. 24	Kuros Biosciences Posts Higher Q1 Product Sales	MT
Apr. 17	Kuros Biosciences AG Approves Board of Director and Committee Changes	CI

Kuros Biosciences AG is a Switzerland-based biotechnology company engaged in the discovery, development and commercialization of biopharmaceutical products known as Immunodrugs. Immunodrugs are therapeutic vaccines intended for treating and preventing common chronic diseases, such as hypertension, nicotine addiction, allergic diseases, asthma, malignant melanoma and Alzheimer's disease. They are designed to instruct the patient's immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. The Company has built a pipeline of different Immunodrug candidates, of which five are in clinical development. Its Immunodrug candidates are developed both in-house and together with Novartis, Pfizer and Pfizer Animal Health, among others. The Company has two subsidiaries: a wholly-owned Proteome Therapeutics GmbH and minority owned BioSupport AG.

CHF in Million	2022	Weight	2023	Weight	Delta
Medical Devices 100.0 %	13	73.8 %	34	100.0 %	+153.03%

CHF in Million	2022	Weight	2023	Weight	Delta
United States 97.8 %	17	96.6 %	33	97.8 %	+88.93%
European Union 1.7 %	0	2.4 %	1	1.7 %	+35.20%
Other 0.4 %	0	1.0 %	0	0.4 %	-17.82%

Managers	Title	Age	Since
Joost de Bruijn FOU	Founder	58	17-12-03
Christopher Fair CEO	Chief Executive Officer	54	21-04-18
Daniel Geiger DFI	Director of Finance/CFO	-	23-02-16
Florence Barrère de Groot CTO	Chief Tech/Sci/R&D Officer	-	16-12-31
Sjoerd Musters COO	Chief Operating Officer	-	22-09-30
Luuk van Dijk CTO	Chief Tech/Sci/R&D Officer	-	14-12-31
Katherine Sage CTO	Chief Tech/Sci/R&D Officer	-	20-12-31
John Griffin PRN	Corporate Officer/Principal	-	23-10-11
Marcel Borger LAW	General Counsel	-	19-12-31
Philippe Saudan PRN	Corporate Officer/Principal	57	16-08-09

Members of the board	Title	Age	Since
Scott P. Bruder BRD	Director/Board Member	62	18-06-13
Christopher Fair CEO	Chief Executive Officer	54	21-04-18
Joost de Bruijn FOU	Founder	58	17-12-03
Clemens A. van Blitterswijk CHM	Chairman	67	17-05-22
Oliver Walker BRD	Director/Board Member	55	18-06-13
Leanna Caron BRD	Director/Board Member	56	16-06-15

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	36,866,049	23,857,779 ( 64.71 %)	17,244 ( 0.0468 %)	64.71 %

Name	Equities	%	Valuation
C A C M Oomen 25.36 %	9,343,733	25.36 %	63 M CHF
Pegasus Global Opportunity Fund Ltd. 5.868 %	2,161,824	5.868 %	15 M CHF
Joost de Bruijn 3.970 %	1,462,455	3.970 %	10 M CHF
KUROS BIOSCIENCES AG 3.149 %	1,160,106	3.149 %	8 M CHF
Banque Pictet & Cie SA 2.976 %	1,096,224	2.976 %	7 M CHF
LSP Management Group BV 2.968 %	1,093,185	2.968 %	7 M CHF
Credit Suisse Asset Management (Schweiz) AG 2.968 %	1,093,185	2.968 %	7 M CHF
Apo Asset Management GmbH 2.868 %	1,056,504	2.868 %	7 M CHF
Migros Bank AG 0.1768 %	65,130	0.1768 %	438 201 CHF
Equinor Asset Management ASA 0.1323 %	48,750	0.1323 %	327 995 CHF

Name	Equities	%	Valuation
KUROS BIOSCIENCES AG 3.15%	1,160,106	3.15%	7,805,309 $

Kuros Biosciences Ltd.

Wagistrasse 25

8952, Schlieren

http://www.kurosbiosciences.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs